BioCentury
ARTICLE | Finance

Foreseeing liquidity

Foresite marks first liquidity event for its late-stage life science portfolio

April 30, 2012 7:00 AM UTC

Foresite Capital has made five investments since its launch last summer, one of which became liquid about a week ago using the Form 10 pathway, the firm's founder and CEO, Jim Tananbaum, told BioCentury.

The firm employs a mix of financing approaches - including debt, equity, structured financing and secondary acquisitions - to invest in drug, device, diagnostics and healthcare services companies. Foresite also uses special purpose acquisition corporations that scale up to $50 million per investment...